Search
for
Sort by
Research 31–60 of 1000+
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System
- 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
- Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
- 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
- Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- A Gender Hypothesis of sex disparities in adverse drug events
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Machine Learning–Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated with Minoxidil
- Machine Learning–Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated with Minoxidil
- Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
- Reporting on Adverse Clinical Events
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Implementing patient safety and quality improvement in dermatology. Part 1: Patient safety science
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Finasteride Use: Evaluation of Depression and Suicide Risk